1. The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.
- Author
-
Skinner-Adams, Tina S, Butterworth, Alice S, Porter, Kimberly A, D'Amico, Ronald, Sawe, Fred, Shaffer, Doug, Siika, Abraham, Hosseinipour, Mina C, Stringer, Elizabeth, Currier, Judith S, Chipato, Tsungai, Salata, Robert, Lockman, Shahin, Eron, Joseph J, Meshnick, Steven R, and McCarthy, James S
- Subjects
Humans ,HIV Infections ,Malaria ,Nevirapine ,Ritonavir ,HIV Protease Inhibitors ,Female ,Lopinavir ,General Science & Technology - Abstract
HIV protease inhibitors (PIs) show antimalarial activity in vitro and in animals. Whether this translates into a clinical benefit in HIV-infected patients residing in malaria-endemic regions is unknown. We studied the incidence of malaria, as defined by blood smear positivity or a positive Plasmodium falciparum histidine-rich protein 2 antigen test, among 444 HIV-infected women initiating antiretroviral treatment (ART) in the OCTANE trial (A5208; ClinicalTrials.gov: NCT00089505). Participants were randomized to treatment with PI-containing vs. PI-sparing ART, and were followed prospectively for ≥48 weeks; 73% also received cotrimoxazole prophylaxis. PI-containing treatment was not associated with protection against malaria in this study population.
- Published
- 2012